Catalog No.
DHJ48702
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG4-kappa
Clonality
Monoclonal
Target
SOST, Sclerostin
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q9BQB4
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
LY2541546, CAS: 1132758-87-2
Clone ID
Blosozumab
Targeting Sclerostin in Postmenopausal Osteoporosis: Focus on Romosozumab and Blosozumab, PMID: 28547661
Romosozumab and blosozumab: alternative drugs of mechanical strain-related stimulus toward a cure for osteoporosis, PMID: 25954248
Molecular genetics and targeted therapy of WNT-related human diseases (Review), PMID: 28731148
The Effect of Discontinuing Treatment With Blosozumab: Follow-up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density, PMID: 25707611
Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women, PMID: 23996473
A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density, PMID: 25196993
Emerging drugs for osteoporosis, PMID: 24995794
Sclerostin and skeletal health, PMID: 25669441
Pharmacometrics and systems pharmacology for metabolic bone diseases, PMID: 30690761
Comparative efficacy between monoclonal antibodies and conventional drugs in postmenopausal women with osteoporosis: a network meta-analysis, PMID: 33302631
New insights into treatment of osteoporosis in postmenopausal women, PMID: 26557374
Biological agents in management of osteoporosis, PMID: 25204309
Anti-sclerostin antibodies: utility in treatment of osteoporosis, PMID: 24842796
Future directions for new medical entities in osteoporosis, PMID: 25432357
Sclerostin Inhibition in the Management of Osteoporosis, PMID: 27016922
Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis, PMID: 26082665
Sclerostin antibodies in osteoporosis: latest evidence and therapeutic potential, PMID: 28974988
Exploiting the WNT Signaling Pathway for Clinical Purposes, PMID: 28432596
Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases, PMID: 24688605
[Pharmacology of bone anabolic agents], PMID: 26529924
Clinical utility of anti-sclerostin antibodies, PMID: 28115281
[The canonical Wnt/β-catenin pathway: From the history of its discovery to clinical application], PMID: 28635854
Romosozumab: a novel bone anabolic treatment option for osteoporosis?, PMID: 31858345
For research use only. Not for human or drug use.
